“The FDA has approved an immunotherapy that could allow some rectal cancer patients to avoid chemotherapy, radiation, and surgery. The drug, called dostarlimab, helps the immune system attack tumors with a certain genetic defect. In a clinical trial involving 154 patients whose tumors had this defect, 71 percent needed no additional cancer treatment and showed no signs of disease progression after a median follow-up of around two years,” notes Human Progress.
Time reports:
Read Full Article: https://libertyunyielding.com/2026/10/31/rectal-cancer-patients-may-avoid-chemotherapy/
